China Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit

MT Newswires Live01-27

Two China Cinda Asset Management (HKG:1359) subsidiaries will inject 285 million yuan into Luye Pharma's (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse filing.

Nanjing Xian'an Investment will contribute 185 million yuan, and Ningbo Xinda Huajian Investment will inject 100 million yuan.

The transaction includes equity option arrangements under which the group's unit, Yantai Luye, holds call options over the Cinda entities' stakes, while Nanjing Xinan and Ningbo Cinda hold put options tied to listing, performance, and control-related trigger events.

The company will also provide a guarantee for Yantai Luye's obligations under the option agreements.

Proceeds from the capital injection will be used to repay existing financial indebtedness and operating liabilities, the filing said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606279121?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 11:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606279121","market":"sh","top_or_hot":-1,"title":"China Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit","media":"MT Newswires Live","content":"<html><body><p> Two <a href=\"https://laohu8.com/S/CCGDF\">China Cinda Asset Management</a> (HKG:1359) subsidiaries will inject 285 million yuan into <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a>'s (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse filing.</p><p>Nanjing Xian'an Investment will contribute 185 million yuan, and Ningbo Xinda Huajian Investment will inject 100 million yuan.</p><p>The transaction includes equity option arrangements under which the group's unit, Yantai Luye, holds call options over the Cinda entities' stakes, while Nanjing Xinan and Ningbo Cinda hold put options tied to listing, performance, and control-related trigger events.</p><p>The company will also provide a guarantee for Yantai Luye's obligations under the option agreements.</p><p>Proceeds from the capital injection will be used to repay existing financial indebtedness and operating liabilities, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Cinda Subsidiaries to Inject 285 Million Yuan into Luye Pharma Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-27 11:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Two <a href=\"https://laohu8.com/S/CCGDF\">China Cinda Asset Management</a> (HKG:1359) subsidiaries will inject 285 million yuan into <a href=\"https://laohu8.com/S/LYPHF\">Luye Pharma</a>'s (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse filing.</p><p>Nanjing Xian'an Investment will contribute 185 million yuan, and Ningbo Xinda Huajian Investment will inject 100 million yuan.</p><p>The transaction includes equity option arrangements under which the group's unit, Yantai Luye, holds call options over the Cinda entities' stakes, while Nanjing Xinan and Ningbo Cinda hold put options tied to listing, performance, and control-related trigger events.</p><p>The company will also provide a guarantee for Yantai Luye's obligations under the option agreements.</p><p>Proceeds from the capital injection will be used to repay existing financial indebtedness and operating liabilities, the filing said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01359","symbol_name":"中国信达","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2606279121","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606279121","pubTimestamp":1769483273,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Two China Cinda Asset Management (HKG:1359) subsidiaries will inject 285 million yuan into Luye Pharma's (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01359":"中国信达","BK1583":"高瓴概念","BK1191":"制药","BK1606":"中医药概念","BK1156":"资产管理与托管银行","02186":"绿叶制药"},"translate_title":"中国信达子公司将向绿叶制药注入2.85亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01359":1,"02186":1},"content_text":"Two China Cinda Asset Management (HKG:1359) subsidiaries will inject 285 million yuan into Luye Pharma's (HKG:2186) oncology unit, Nanjing Luye Pharmaceutical, according to a Tuesday Hong Kong bourse filing.Nanjing Xian'an Investment will contribute 185 million yuan, and Ningbo Xinda Huajian Investment will inject 100 million yuan.The transaction includes equity option arrangements under which the group's unit, Yantai Luye, holds call options over the Cinda entities' stakes, while Nanjing Xinan and Ningbo Cinda hold put options tied to listing, performance, and control-related trigger events.The company will also provide a guarantee for Yantai Luye's obligations under the option agreements.Proceeds from the capital injection will be used to repay existing financial indebtedness and operating liabilities, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606279121","isCrawlerRequest":true}